First AD

Second AD

Overview of Advanced Therapies in cGVHD

Video content above is prompted by the following:

Both ruxolitinib and ibrutinib are approved for use in cases of cGVHD that have failed 1 or more lines of systemic therapy.

Briefly summarize and critique clinical trial data with ruxolitinib (REACH3) and ibrutinib (Miklos D, et al. 

Comment on adverse effects most frequently seen with ruxolitinib and ibrutinib and how you manage them.

In which patients would you hesitate to use ruxolitinib or ibrutinib (eg, patients at risk of developing thrombocytopenia, etc)?

Belumosudil is approved for treatment of cGVHD after failure of 2 or more systemic therapies. Can you elaborate on anti-inflammatory and antifibrotic properties of belumosudil and results from preclinical and human studies in reduction of fibrosis (Flynn R, et al. 

How do these properties distinguish belumosudil from other targeted therapies for cGVHD?

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Optimizing Treatment for Chronic GVHD

Medical experts discuss advanced therapies in cGVHD. 